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Little is known about airway inflammatory markers in chronic obstructive pulmonary disease (COPD). The objective of the
present study was to identify and try to correlate pulmonary and peripheral blood inflammatory markers in COPD. In a cross-
sectional study on patients with stable COPD, induced sputum and blood samples were collected for the determination of C-
reactive protein, eosinophilic cationic protein, serum amyloid A protein, α-1 antitrypsin (α-1AT), and neutrophil elastase.
Twenty-two patients were divided into two groups according to post-bronchodilator forced expiratory volume in the first second
(%FEV1): group 1 (N = 12, FEV1 <40%) and group 2 (N = 10, FEV1 ≥40%). An increase in serum elastase, eosinophilic cationic
protein and α-1AT was observed in serum markers in both groups. Cytology revealed the same total number of cells in groups
1 and 2. There was a significantly higher number of neutrophils in group 1 compared to group 2 (P < 0.05). No difference in
eosinophils or macrophages was observed between groups. Serum elastase was positively correlated with serum α-1AT (group
1, r = 0.81, P < 0.002 and group 2, r = 0.83, P < 0.17) and negatively correlated with FEV1 (r = -0.85, P < 0.03 and -0.14, P < 0.85,
respectively). The results indicate the presence of chronic and persistent pulmonary inflammation in stable patients with COPD.
Induced sputum permitted the demonstration of the existence of a subpopulation of cells in which neutrophils predominated. The
serum concentration of all inflammatory markers did not correlate with the pulmonary functional impairment.
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Introduction
Chronic obstructive pulmonary disease (COPD) has
recently been defined as a systemic pulmonary inflamma-
tory disease whose physiopathology is poorly understood
(1), with a growing interest in the understanding of the
relationship between systemic inflammation and pulmo-
nary events (2). The balance between pro-inflammatory
and anti-inflammatory mediators determines the course of
an inflammatory process and these mediators involved in
COPD have been less studied than those involved in
asthma (1).
Systemic inflammation has been recognized as an
important risk factor for a diverse number of co-morbidities
including atherosclerosis (3), cachexia (4), anorexia (5),
and osteoporosis (6). Notably, all of these complications
are commonly observed in patients with COPD (7). How-
ever, the extent of systemic inflammation in stable patients
and the nature of the inflammatory markers present during
the chronic phase of the disease have not been demon-
strated.
Neutrophils are the predominant cells in this type of
pulmonary inflammation (8). Elevated levels of mediators
such as interleukin-6, -8, C-reactive protein, eosinophilic
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cationic protein (ECP), elastase, α-1 antitrypsin (α-1AT),
myeloperoxidase, and serum amyloid A protein (SAA)
have been detected in the blood of patients with COPD,
even during exacerbations (9,10). SAA and C-reactive
protein are related to neutrophil chemotaxis (11,12). C-
reactive protein is an acute-phase protein and a sensitive
indicator of systemic inflammation.
Little information is available regarding the airway in-
flammatory markers present in patients with moderate or
severe COPD (13), with this inflammation being character-
ized by elevated numbers of neutrophils and macrophages
in the airways (14). Neutrophils are the main producers of
proinflammatory mediators such as cytokines and pro-
teases (15) and the induced sputum technique permits the
investigation of these patients (16,17). Inflammation and
oxidative stress can be evaluated not only in the airways
and other pulmonary compartments but also in blood (18).
Is it possible to demonstrate in peripheral blood the
repercussions of inflammatory alterations that occur in the
airways and lungs? The purpose of the present study was
to assess the relationships between serum inflammatory
markers, induced sputum and lung function in these pa-
tients. A correlation between these findings might be use-
ful for the medical management of these patients.
Patients and Methods
A cross-sectional study was conducted in which pa-
tients were recruited from the COPD outpatient clinic of the
Pulmonary Division, Heart Institute (InCor), University of
São Paulo Medical School, São Paulo, SP, Brazil. The
Ethics Committee of the Institution approved the study,
and all selected patients signed an informed consent form.
Inclusion and exclusion criteria
The criteria for inclusion in the study were: patients with
COPD according to the criteria established by the Ameri-
can Thoracic Society (ATS) (19), patients of both genders
ranging in age from 40 to 85 years, patients clinically stable
for at least 8 weeks, and patients not taking antibiotics or
anti-inflammatory drugs such as inhaled or oral corticoste-
roids. Exclusion criteria were patients with a past or current
history of basal airway inflammation such as allergic expo-
sure and/or respiratory tract infections that might interfere
with the evaluation and patients with a history or diagnosis
of severe heart disease, asthma, and bronchiectasis or
tuberculosis sequelae.
A COPD exacerbation in the last year was defined in
the protocol as “a sustained worsening of the patient’s
condition, from the stable state and beyond normal day-to-
day variations, that is acute in onset and necessitates a
change in regular medication in a patient with underlying
COPD” (20).
Lung function and induced sputum
The patients were submitted on the same occasion to
spirometry performed according to the criteria of the ATS
(21) and the following parameters were determined: forced
vital capacity (%FVC), forced expiratory volume in the first
second in relation to the predicted values (%FEV1), and
FEV1/FVC actual ratio, and the values are reported as
percent predicted. The patients discontinued a short-act-
ing bronchodilator at least 12 h and a long-acting bron-
chodilator 24 h before the spirometry. Spirometry was
carried out before and 15-20 min after the administration of
400 µg salbutamol inhaled via a spacer device and groups
were defined according to post-bronchodilator spirometry.
Sputum was collected and analyzed as described pre-
viously (22,23). Briefly, sputum was induced after three
sequential inhalations of 3% hypertonic saline for 7 min
each. The aerosol was generated with an ultrasonic nebu-
lizer (Ultra-Neb 99, DeVilbiss, Somerset, PA, USA) with an
output of 2.4 mL/min. The sputum sample was considered
adequate if it met the following criteria: sputum induction
tolerated for at least 14 min, sputum volume >2 mL, pres-
ence of squamous cells ≤80%, at least 200 inflammatory
cells per slide (10 µL), and examination of sputum per-
formed within 2 h. Sputum samples were separated from
saliva with the help of an inverted microscope. At least 200
cells were counted and classified as eosinophils, lympho-
cytes, neutrophils, macrophages, squamous cells, goblet
or ciliated cells based on their morphology.
Inflammatory mediators
After sputum induction, blood samples were collected
for the determination of the following inflammatory mark-
ers in serum and plasma: C-reactive protein (Dako AIS,
Glostrup, Denmark), ECP (fluoroenzyme immunoassay,
Pharmacia and Upjohn Diagnostics, Uppsala, Sweden),
SAA (enzyme immunoassay, Hemagen, São Paulo, SP,
Brazil), α-1AT (Alpha Diagnostics, San Antonio, TX, USA),
and neutrophil elastase (Merck, Darmstadt, Germany).
Statistical analysis
Data are reported as median and 95% confidence
range or mean and standard deviation and were analyzed
statistically using appropriate software (SPSS No. 10 soft-
ware program, Chicago, IL, USA). The normal distribution
of the variables was evaluated by the Kolmogorov-Smirnov
test. Differences between groups were determined by the
Student t-test and Kruskal-Wallis test. Correlations be-
tween variables were calculated using the Spearman cor-
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relation test. A P value < 0.05 was considered to be
significant. The patients were stratified by functional in-
volvement (24) into group 1, FEV1 <40% of predicted
value, and group 2, FEV1 ≥40% of predicted value, always
post-bronchodilator. Since this was a pilot study, we did
not calculate the sample size.
Results
Thirty-three subjects were selected and 22 who per-
formed all procedures were included. Among the 11 pa-
tients who were excluded, eight did not fulfill the criteria for
acceptance of the sputum sample and three had broncho-
spasm during induction, which prevented collection of the
sputum sample. However, no clinical difference was ob-
served between included and excluded patients. None of
the patients had smoked actively for at least 6 months prior
to the study; received inhaled or oral corticosteroids, or
other systemic drugs including theophylline, antibiotics or
nonsteroidal anti-inflammatory drugs, or reported any acute
exacerbations for at least eight weeks prior to sputum
induction.
The clinical and functional characteristics of the pa-
tients included in the study are shown in Table 1, with 12
patients in group 1 (FEV1 <40%) and 10 patients in group
2 (FEV1 ≥40%). There was a predominance of males in
both groups and the mean age was 60 years. All patients
were long-term heavy smokers (mean pack-years = 74).
The mean time since the diagnosis of COPD was at least 8
years in both groups. The mean time since smoking cessa-
tion was 8 years for group 1 and 14 years for group 2. At
least 4 patients in group 1 and 2 in group 2 had used oral
corticosteroids (20 mg/day for 10 days) in the last year.
Exacerbation in the last year was observed for 4 patients in
group 1 and 2 in group 2. No significant difference in these
variables was observed between groups.
The pulmonary function test revealed an important
reduction of FEV1 and FEV1/FVC ratio in patients of group
1 (P < 0.001) compared to group 2, and FVC was also
lower in group 1 but the difference was not significant.
None of our patients had a bronchodilator response after
400 µg of inhaled salbutamol.
An increase was observed in the serum inflammatory
markers of neutrophil (elastase) and eosinophil (ECP)
activity and α-1AT in the two groups when compared to the
reference values of the kits used. There was no difference
in C-reactive protein or SAA levels compared to the refer-
ence values of the respective kits (Table 2).
The total number of cells in sputum of groups 1 and 2
was not significantly different. A significantly greater num-
ber of neutrophils was observed in group 1 (6.5 (1.6-37) x
Table 1. Clinical and functional characteristics of patients with
chronic obstructive pulmonary disease (COPD).
Group 1 Group 2
(N = 12) (N = 10)
Male/female 10/2 9/1
Age (years) 65 (52-85) 55 (43-77)
Pack-years 78 ± 11 70 ± 13.5
Smoker/ex-smoker 1/11 4/6
Years since smoking cessation 8 (1-20) 14 (1-40)
On oral corticosteroids (yes/noa) 4/8 2/8
Duration of COPD (years) 7.5 ± 1.1 8.5 ± 1.8
Exacerbations (yes/nob) 4/8 2/8
FVC (% predicted) 64 ± 5.7 73 ± 3.3
FEV1 (% predicted) 30 ± 1.8 50 ± 2.3*
FEV1/FVC ratio (% predicted) 47 ± 3.1 68 ± 1.1*
Data are reported as mean ± SD or as otherwise indicated.
Group 1 = FEV1 <40% predicted; group 2 = FEV1 ≥40% pre-
dicted; FVC = forced vital capacity; FEV1 = forced expiratory
volume in the first second. aNo use of oral corticosteroids in the
last year. bNo exacerbations in the last year. Dose of oral cortico-
steroids: 20 mg/day for 10 days.
*P < 0.001 compared to group 1 (t-test).
Table 2. Serum markers of inflammatory activity in patients with
chronic obstructive pulmonary disease.
Group 1 Group 2 Reference value
(N = 12) (N = 10) (lower limit
of detection)
Elastase (µg/L) 58 ± 7.4 46 ± 9 12-32 (8)
ECP (µg/L) 13 ± 2 22 ± 6* 2-10 (0.5)
α-1AT (mg/dL) 205 ± 22 215 ± 20 83-199 (20)
CRP (mg/dL) 0.19 (0.13-0.87) 0.63 (0.16-1.4)* ≤0.5 (0.2)
SAA (µg/L) 3.5 (3-4.5) 5.2 (4-20)* 3-4 (2)
Data are reported as mean ± SEM or median and 95% confi-
dence interval for C-reactive protein and SAA. Group 1 = FEV1
<40% predicted; group 2 = FEV1 ≥40% predicted; ECP = eosi-
nophilic cationic protein; α-1AT = α-1 antitrypsin; CRP = C-
reactive protein; SAA = serum amyloid A protein.
*P < 0.05 compared to group 1 (t-test).
106 cells/mL) compared to group 2 (3.2 (1.3-11.8) x 106
cells/mL) (P < 0.05). No difference in eosinophils, macro-
phages or lymphocytes was observed between groups
(Figure 1).
Serum elastase was positively correlated with α-1AT in
both group 1 and group 2 (r = 0.81, P < 0.002 (Figure 2) and
r = 0.83, P < 0.17, respectively). A negative correlation was
observed between FEV1 and elastase in group 1 and
group 2 (r = -0.85, P < 0.03 (Figure 3) and r = -0.14, P <
0.85, respectively).
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Figure 1. Range and distribution of sputum cellularity in patients
with chronic obstructive pulmonary disease. Data are reported
as box plots showing the median (line inside), the interquartile
range (25th to 75th percentiles), the bars (10th and 90th percen-
tiles), and outliners (closed circles) for sputum cellularity com-
paring group 1 with FEV1 <40% and group 2 with FEV1 ≥40%.
NE = neutrophils; EO = eosinophils; MA = macrophages; LY =
lymphocytes. For statistical analysis the Wilcoxon signed rank
test was used.
Figure 2. Correlation between serum elastase and serum α-1
antitrypsin (α-1AT) in patients of group 1 (FEV1 <40%).
Figure 3. Correlation between serum elastase and forced expira-
tory volume in the first second (FEV1) post-bronchodilator in
group 1 (FEV1 <40%).
Discussion
The results obtained for patients with moderate and
severe COPD, indicated the presence of chronic and per-
sistent pulmonary inflammation in stable patients. The use
of induced sputum permitted the demonstration of the
existence of a subgroup in which neutrophils predomi-
nated and of another in which these cells did not. Serum
inflammatory markers did not correlate with the degree of
pulmonary function impairment in this group of stable
patients with COPD.
An elevated number of neutrophils in sputum were
observed in the two groups when compared with asthmatic
patients or normal subjects (25), with the number of these
cells being higher in the group presenting greater func-
tional impairment (group 1). The predominance of neutro-
phils in sputum observed for group 1 is in agreement with
data reported in the literature (15,25,26). Neutrophils pos-
sess granules that contain proteins such as myeloperoxi-
dase and lipocalin. These neutrophil markers have been
shown to be elevated in sputum of patients with COPD,
indicating the degranulation of primary and secondary
granules in neutrophils (25).
The extracellular matrix of the lung is a dynamic struc-
ture whose integrity requires a balance between the syn-
thesis and degradation of its components. Neutrophils are
the main source of elastase in the human lung (27), fol-
lowed by macrophages. Elastase secreted by these cells
destroys structural pulmonary components and thus con-
tributes to obstruction (28). Several studies have sug-
gested that the activity of proteolytic enzymes, particularly
neutrophil elastase, plays an important pathogenic role in
the development of emphysema (29-31). An increase in
the degradation of elastin in the organism is observed
during periods of COPD exacerbation (32).
Neutrophils and T lymphocytes are related to the de-
gree of obstruction and airflow limitation observed in pa-
tients with COPD (14,33). In the present study, an increase
in neutrophil elastase and an impairment in %FVC, %FEV1,
and in FEV1/FVC were observed in the two groups, with
these findings being more expressive in group 1.
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The main inhibitor of elastase is α-1AT (34), a serum
protein that functions as an endogenous inhibitor of serine
proteinases. Serum α-1AT levels were also found to be
higher than normal in the two groups of patients with COPD,
with no significant difference between groups. In group 1, the
elevated elastase levels were positively correlated with the
increase in α-1AT and negatively correlated with FEV1.
Our results support the thesis that pulmonary obstruc-
tion is a consequence of the presence of inflammatory
stimuli (35-37). One hypothesis can be raised to explain
the development of tissue damage associated with COPD
and suggests an imbalance between proteases and anti-
proteases and the other proposes changes in the oxidant-
antioxidant ratio (1).
We also investigated markers of systemic inflamma-
tion, including C-reactive protein and SAA, and correlated
them with COPD. Some studies have demonstrated el-
evated C-reactive protein levels in COPD during exacer-
bations, indicating the possible presence of infection
(10,38), and in stable COPD patients (39,40), and elevated
SAA levels in asthma. No expressive increase in C-reac-
tive protein was observed, a finding that might be ex-
plained by the fact that the population consisted of stable
severe patients. Curiously, SAA and C-reactive protein,
even within the reference values of the kit, were found to be
more elevated in group 2, with the increase in SAA being
significant when compared to group 1.
One limitation of our study was the fact that the study
population presented an advanced degree of pulmonary
function impairment. Thus, the present findings are limited
to patients with a similar degree of pulmonary involvement
secondary to smoking. Therefore, caution may be neces-
sary when using the serum and sputum inflammatory
mediator in COPD patients. Because the comparison be-
tween outcomes of the serum and sputum was performed
in only a limited number of patients, further studies should
focus on a large number of individuals. However, the
power of our results was tested, and it was found to be
>80%. Therefore, a type 1 statistical error is unlikely.
Despite these limitations, the analysis of inflammatory
markers can be an important tool to better understand the
physiopathological alterations that occur in COPD. To-
gether with the analysis of pulmonary function, this ap-
proach may contribute to the understanding of clinical
variables and permit a better treatment guidance of these
patients.
These results may have implications for our under-
standing of the pathogenesis of the disease. The results
indicate the presence of chronic and persistent pulmonary
inflammation in stable patients with COPD. These results
confirm the presence of inflammatory processes in the
airways and circulation of patients with COPD. Knowledge
of the relationship of these inflammatory markers allows us
to design clinical trial of anti-inflammatory therapies that
include appropriate outcomes.
In summary, therefore, we have assessed the interre-
lationship between serum inflammatory markers, induced
sputum and lung function in patients with stable COPD
with a wide range of bronchial disease. Although relation-
ships can be demonstrated, it is clear that they are com-
plex, and understanding the interplay of various mediators
will require appropriately designed intervention studies.
Further studies are needed to determine whether attenua-
tion of the systemic inflammatory process can modify the
risk of complications in COPD.
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